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Fibrocytes are myeloid lineage cells implicated in wound healing, repair, and fibrosis. 
We previously showed that fibrocytes are mobilized into the circulation after vascular 
injury, including the immune-mediated injury that occurs after allogeneic transplantation. 
A common response to inflammatory vascular injury is intimal hyperplasia (IH), which, 
alongside vascular remodeling, results in progressive loss of blood flow, downstream 
ischemia, and end-organ fibrosis. This forms the pathological basis of transplant arte-
riosclerosis and other diseases including post-angioplasty re-stenosis. In investigating 
whether fibrocytes contribute to IH, we previously showed that subpopulations expressing 
smooth muscle actin and CD31 are recruited to the site of injury and accumulate in the 
neointima. Expression of tissue factor (TF) by these “CD31+ myofibrocytes” is needed 
for progressive neointimal expansion, such that TF inhibition limits the neointima to a 
single layer of cells by day 28 post-injury. The aim of this study was to determine patho-
physiological mediators downstream of TF that contribute to myofibrocyte-orchestrated 
IH. We first show that myofibrocytes make up a significant component of the neointima 
28 days following injury. Using a previously defined adoptive transfer model, we then 
show that CD31+ myofibrocytes get recruited early to the site of injury; this model allows 
manipulations of the adoptively transferred cells to study how IH develops. Having con-
firmed that inhibition of TF on adoptively transferred cells prevents IH, we then show that 
TF, primarily through the generation of thrombin, induces secretion of angiopoietin-2 by 
myofibrocytes and this directly stimulates proliferation, inhibits apop tosis, and induces 
CXCL-12 production by neointimal cells, including non-fibrocytes, all of which promote 
progressive IH in  vivo. Prior incubation to inhibit angiopoietin-2 secretion by or block 
TIE-2 signaling on adoptively transferred fibrocytes inhibits IH. These novel data indicate 
that angiopoietin-2 production by early recruited myofibrocytes critically influences 
the development of IH after vascular injury and suggest new therapeutic avenues for 
exploration.
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inTrODUcTiOn
Chronic vascular disease commonly involves intimal hyperplasia 
(IH) and remodeling of arteries, leading to progressive reduction 
in blood flow, tissue fibrosis, and eventual organ failure. IH is 
characterized by progressive accumulation of cells expressing 
α-smooth muscle actin (SMA) in the intima: the precise origin 
of these cells has been extensively debated, but several studies in 
mice (1) and humans (2) suggest that some of these cells can be 
bone marrow (BM)-derived (3).
Working in both wire-induced endoluminal injury and allo-
geneic aortic transplantation models (4), we previously showed 
that a BM-derived cell type had a critical influence on the devel-
opment of IH (5, 6). Subsequently, we identified that a monocyte-
derived cell type was an early constituent of the neointima. 
We characterized these as CD45+ cells expressing CD31, TIE-2, 
VEGF-R2, and E-selectin (5), a phenotype consistent with pre-
vious descriptions of a neointimal cell type (7). Importantly, 
these CD45+ cells also expressed CD34 and collagen-1, identify-
ing them as a fibrocyte subset. We also showed that fibrocytes 
were mobilized into the peripheral blood of mice post-injury 
and post-transplantation, accounting for approximately 45% of 
all CD34+ cells mobilized.
This offered an opportunity to develop adoptive transfer 
models, whereby circulating CD34+ cells isolated by magnetic 
bead-depletion from post-injury donor mice, and containing 
fibrocytes, are transferred to secondary host mice either on the 
day of injury or 7 days post-transplantation, depending on the 
model (4, 5, 8). Under these conditions, using cells harvested from 
donor mice expressing yellow fluorescent protein in all cells, we 
showed that the transferred CD34+ cells are recruited early to the 
injured host vessel wall. CD34+ cells from wild-type (WT) donor 
mice (but not CD34-negative cells) can transfer IH into a strain 
of host mice that are resistant to IH (4, 6), confirming that circu-
lating CD34+ cells mobilized post-injury in the donor have an 
important role in orchestrating the intimal proliferative response 
following injury or allotransplantation. Moreover, donor CD34+ 
cells transferred into hosts either 2 weeks post-injury or 3 weeks 
post-transplantation get recruited to the neointima, suggesting 
that continuous recruitment of fibrocytes from the circulation 
may have an important influence on the progressive accumula-
tion of cells in the neointima (5).
Neointimal fibrocytes express tissue factor (TF), and two 
strains of transgenic (Tg) mice expressing a membrane-tethered 
inhibitor of TF-FVIIa-FXa [human tissue factor pathway inhi-
bitor (hTFPI)] on different cells (6, 9, 10) have been useful tools 
to dissect the importance of coagulation proteases in these 
models. Moreover, the hTFPI can be used to isolate and track 
cells in vivo.
In one of the strains, called “CD31-TFPI-Tg” mice, hTFPI 
expression is found in all CD31+ cells (10), but within the 
CD34+ fraction, only SMA+ fibrocytes (myofibrocytes) express 
the hTFPI on the cell surface (8). In this strain, although these 
CD31+ myofibrocytes are recruited to the vessel wall post-injury, 
no IH develops, and adoptive transfer of CD34+ cells from 
these mice to injured WT mice inhibits the development of IH, 
a phenotype that is due to the expression of the hTFPI transgene, 
as an inhibitory anti-hTFPI antibody reverses the protection 
offered by the hTFPI (8).
In this paper, we investigated the molecules downstream of 
TF and thrombin-mediated signaling, focusing on the role and 
importance of angiopoietin-2. Our data provide novel insights 
into the cellular and molecular basis of IH and should provide 
a foundation for exploring novel pathophysiological and thera-
peutic avenues in translational research.
MaTerials anD MeThODs
animals and experimental Models
Wild-type mice (C57BL/6 from Harlan Olac Ltd., Bicester, UK), 
heterozygous CD31-TFPI-Tg (10), and ROSA-enhanced yellow 
fluorescent protein (EYFP) (5) mice, were bred and maintained 
at King’s College London. All genetically modified animals have 
been maintained for more than 10 generations on a WT back-
ground. All procedures were approved by the UK Home Office.
Wire-Induced Endoluminal Carotid Artery Injury
Mice weighing 25–30  g (n =  6 per group) were anesthetized 
by intraperitoneal injection of 0.1  ml/10  g solution composed 
of 1  ml Hypnorm solution (0.315  mg fentanyl/ml and 10  mg 
fluanisone/ml) (VetaPharma Ltd., Leeds, UK), 1  ml Hypnovel 
solution (5 mg Midazolame/ml) (Roche, Garden City, UK), and 
2 ml dHO2. Surgery was performed using a dissecting micro -
scope (Stemi SV 6, ZEISS, Germany). A 0.015-inch angioplasty 
guide wire (Cook Incorporated, IN 47404, USA) was introduced 
into the exposed left common carotid via the external carotid 
artery and withdrawn/reinserted three times to denudate 
endothelial layer. The external carotid artery was ligated after 
removing the wire. After confirming restoration of normal blood 
flow, animals were allowed to recover. To block the function of 
human TFPI in CD31-Tg mice, some animals from each strain 
(n = 6 each group) were administrated with 80 ng/g anti-human 
TFPI in 50  µl saline (Enzyme Research Laboratories, Swansea, 
UK) or isotype control mAb at a same dose by tail vein immedi-
ately after wire-induced injury.
Adoptive Transfer of CD34+ Cells After  
Vascular Injury
CD34+ cells were purified from donor mice 2–4  days after 
injury. Briefly, murine peripheral blood was collected into 1 mM 
EDTA or 3.2% sodium citrate and diluted with 2% FCS-PBS. 
Pelleted cells were re-suspended in ACK buffer and left at room 
temperature for 25  min, before washing to remove platelets. 
Purified CD34+ cells were isolated using magnetic beads 
(Miltentyi Biotech, Surrey, UK) as previously described (5, 6) 
and had an average purity of 95%. 1 ×  106 CD34+ cells, or 
purified fractions were injected into a second mouse via a tail 
vein on the day of injury. In some experiments, CD34+ cells 
were incubated with 100 µg/ml rat anti-mouse TF antibody (11) 
or 10  µg/ml anti-mouse TIE-2 antibody (Abcam, Cambridge, 
UK) and equal dose of isotype control antibodies, or 250 pmols 
siRNA/ml (see below) for 1 h in a 24-well plate, immediately 
prior to injection.
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Morphometric analysis and 
immunohistology
Carotid arteries were embedded in optimum cutting tempera-
ture compound (OCT) (VWR International, Dorset, UK) before 
cross-sectioning. Morphometric analysis was performed after 
staining with the Accustain Elastin Stain kit (Sigma) and evalu-
ation on an Olympus U-ULH microscope (Olympus Optical 
Co Ltd., Tokyo, Japan). Medial and neointimal area were deter-
mined with Image-Pro Plus TM software version 4.0 (Media 
Cybernetics, Silver Spring, MD, USA). At least three random 
sections were examined from each of six wire-injured arteries, 
by an investigator blinded to the identity of the sections. For 
immu nofluorescence (IF) analysis, carotid arteries were excised 
and embedded in OCT (VWR), and cut into 5  µm sections 
before fixing in methanol for 60 min at −20°C. Frozen sections 
were immersed in 1% BSA(Sigma)-PBS for 30  min and then 
incubated overnight at 4°C with the following antibodies: goat 
anti-angiopoietin-2 (Santa Cruz biotechnology Inc.), mouse 
mono clonal anti-collagen 1 (as a marker of fibocytes), rabbit 
anti-CXCR4, rabbit anti-CXCL12 (all from Abcam), mouse 
anti-human TFPI (Enzyme Research Laboratories, Swansea, 
UK), and rat anti-mouse CD31(BD). All stained sections were 
mounted in Vectashield mounting medium with DAPI (Vector 
Laboratories). Sections were examined by a Leica DM-IRBE 
confocal microscope (Leica, Wetzlar, Germany) equipped with 
Leica digital camera AG and a confocal laser scanning system 
with excitation lines at 405, 488, 543, and 560 nm at magnifica-
tions 10×/0.40CS and 20×/0.70IMM (Leica, Planapo, Wetzlar, 
Germany). Images were processed using Leica-TCS-NT soft-
ware associated with the Leica confocal microscope. For analysis 
of the neointimal area occupied by specific stains, data were 
collected from three random sections from each of six arteries, 
with the investigator blinded to the identity. For all molecules, 
control sections were stained with isotype-matched antibodies 
to confirm the specificity of staining (see Figure S1 in Supple-
men tary Material).
Thrombin generation, chemokine, and 
angiopoietin Production
CD34+ cells (2 × 104 per well in a 96-well plate) were washed 
and suspended in Dulbecco modified Eagle medium (DMEM; 
Sigma-Aldrich MO, USA) containing 10 nmol/l Factor X (FX) 
with or without 10 nmol/l factor VIIa (FVIIa) at 4°C. After 15 min, 
pre-prepared 10  nmol/l factor Va (FVa) and 0.5  µmol/l pro-
thrombin (all from Enzyme Research Laboratories) in HEPES- 
buffered saline (Life Technologies, Grand Island, NY, USA) 
were added. At defined times, aliquots of the reaction mixture 
were transferred into Tris-EDTA buffer with the chromogenic 
substrate S-2238 (Chromagenix, Milan, Italy) to assess thrombin 
generation. Absorbance at 405 nm was converted to concentra-
tions using purified standards control assays. To assess production 
of angiopoietin-2 and CXCL12 under these conditions, the assay 
was terminated after 20 min by washing the cells five times with 
PBS before re-culturing in DMEM containing 2% FCS for 24 h 
to obtain supernatant. To assess angiopoietin-2 and CXCL-12 
production after thrombin stimulation, 2 × 104 CD34+ cells were 
seeded on a round glass coverslip in a 24-well plate, serum starved 
for 24  h, following which varying concentrations of thrombin 
(0–100  nmol/l) (Enzyme Research Laboratories, Swansea, UK) 
were added, with or without an anti-TIE-2 antibody (Abcam) 
before incubation in Iscove modified Dulbecco medium (IMDM; 
Sigma-Aldrich, MO, USA) supplemented with 2% fetal bovine 
serum (FBS; StemCell Technology, Grenoble, France) for 5 days.
To assess PAR-induced cell signaling, starved cells were treated 
with 0–20  µM of either PAR-1, PAR-2, or PAR-4 antagonists 
(Peptides International, Louisville, KY, USA) for 30 min before 
stimulation with FVIIa + FX or FVIIa + FX + FII at indicated 
doses; or cells were stimulated with 0–100 µM of PAR-1, PAR-2, 
or PAR-4 agonist (Peptides International); or cells were treated 
first with or without 50  µM mitogen-activated protein kinase 
inhibitor PD98059, 10 µM p38-MAPK inhibitor SB203580, 20 µM 
NF-kB inhibitor SN50, and 1 µM of the S6K1 inhibitor (All from 
Merck Millipore, Hertfordshire, UK) for 30 min and then stimu-
lated with 10 µM of PAR-1, PAR-2, or PAR-4 agonist. 24 h after 
cell treatments, angiopoietin-2 concentration was determined 
in supernatants. In some assays, cells were first treated with the 
siRNA for angiopoietin 2 or the fluorescein conjugated control 
siRNA, using 2 × 105 CD34+ cells per well were seeded in a six-
well tissue culture plate (see below).
Angiopoietins-1 and -2 and CXCL12 were quantified using 
commercially available ELISA kits (Cusabio Biotech, DE19711, 
USA) according to the manufacturer’s protocol. The minimum 
detectable dose is less than 0.1 pg/ml for mouse angiopoietin-1 
and 0.08 pg/ml for mouse angiopoietin-2. The same procedure 
was used to analyze plasma levels.
sirna Transfection
siRNA for angiopoietin 2 (sc-39294), a pool of 3 target-specific 
19-25 nt siRNAs designed to knockdown gene expression, and 
the fluorescein conjugated control siRNAs (sc-36869) were pur-
chased from Santa Cruz biotechnology Inc. Texas 75220, USA. 
2 ×  105 CD34+ cells per well were seeded in a six-well tissue 
culture plate and transiently transfected using siRNA transfec-
tion reagents system (Santa Cruz Biotechnology Inc.) according 
to the manufacturer’s instructions. For in vitro use, 2 × 105 cells 
per well were incubated with 50 pmols siRNA diluted into siRNA 
transfection medium. 24 h after transfection, cells were washed 
twice in serum-free medium and incubated with 50 nM throm-
bin for further incubation with the culture medium containing 
2% FCS. 48 h later, cells were collected for assaying cell prolifera-
tion, fixed for analyzing cell phenotype and apoptosis and super-
natants harvested for measuring angiopoietin 2 and CXCL12 
productions. For in vivo use, see above.
cell Proliferation and apoptosis
To determine cell proliferation, CD34 cells were seeded at 
104cells/well in 96-well plate. After the manipulations defined 
above, wells were pulsed with 0.037  MBq/ml (1  Ci/ml) [3H]- 
thymidine (Amersham Biosciences, Bucks, UK) for the last 18 h 
of culture and then harvested using a Micro 96 harvester (Skatron 
Instruments, Lier, Norway) and the incorporation of [3H] thymi-
dine was determined using a liquid scintillation counter (1205 
Betaplate; Wallac, Turku, Finland). Apoptosis was performed 
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with an in  situ cell death detection kit according to the manu-
facturer’s instructions (Roche Applied Science, Philadelphia, 
PA, USA). All analyses were performed in triplicate.
immunohistochemistry and 
immunocytochemistry
CD34+ cells were spread on a glass coverslip (VWR Interna-
tional, Leuven, Belgium) and fixed with cold methanol for 
10  min at −20°C, before incubation with specific antibodies 
at room temperature for 60 min. Cells were then incubated at 
room temperature for 60 min with following antibodies: mouse 
anti-human α-SMA conjugated with Cy3 (Sigma-Aldrich, 
St. Louis, MO, USA), rat anti-mouse CD31 (BD) and rabbit anti-
collagen-1, rabbit anti-angiopoietin-1, rabbit anti-angiopoietin-2, 
rabbit anti-TIE-2, and rabbit anti-CXCL12 (all from Abcam). 
Second layer staining was with a goat anti-rat IgG-FITC, a goat 
anti-rabbit IgG-FITC, and a rabbit anti-goat IgG-FITC (all from 
Sigma-Aldrich). Stained cells were mounted in Vectashield 
mounting medium with DAPI (Vector Laboratories), and cap-
tured by a Leica DMIRBE confocal microscope (Leica, Wetzlar, 
Germany) as above.
statistical analysis
Statistical analysis was performed with GraphPad Prism soft-
ware. The Mann–Whitney test was used for comparison of two 
groups and the Kruskal–Wallis test for ≥3 groups. All data were 
reported as mean ± SEM. A value of P < 0.05 was considered 
statistically significant.
resUlTs
Vailidity of adoptive Transfer Model  
to study the role of angiopoietin-2 
expressed by Myofibrocytes in 
Pathophysiology of ih
In WT Mice, Angiopoietin-2+ Myofibrocytes 
Recruited to Site of Endoluminal Injury Make  
Up a Significant Proportion of Neointima
Following wire-induced injury, we have previously shown that 
myofibrocytes are quickly mobilized into the circulation, reach-
ing peak numbers by 2–3 days (5, 8). We confirmed in this new 
work that these cells get recruited to the luminal aspect of the 
injured vessel, so that collagen-1+ cells are easily detectable by 
day 7 and make up ≥50% of the neointimal area for up to 28 days 
post-injury (Figure  1A). Many of these cells co-expressed 
angiopoietin-2 (Figure 1A) but a significant proportion of the 
angiopoietin-2 expression was in collagen-1-negative, areas, 
suggesting that angiopoeitin-2 was expressed by cells in the 
neointima other than myofibrocytes. This data re-affirm that 
the response to endoluminal injury involves recruitment of 
myofibrocytes, that these comprise a significant proportion of 
the neointimal area 28 days post-injury, and that they express 
angiopoietin-2.
Adoptive Transfer of CD34 Cells Results  
in Recruitment of Donor Myofibrocytes  
to the Site of Injury
As previously described, CD34+ cells from WT mice were adop-
tively transferred into secondary host WT mice immediately 
following endoluminal injury. Collagen-1+ cells were detectable 
at the site of injury within several hours after injection (Figure 1B), 
occupied a slightly larger proportion of neointimal area as in 
WT mice without adoptive transfer, and co-expressed angio-
poietin-2 (Figure  1B). Expression of angiopoietin-2 by non-
fibrocytes was similar to that seen without adoptive transfer. 
Confirmation that the adoptively transferred cells were recruited 
to the neointima came from the transfer of CD34+ cells from 
EYFP mice (Figure  1C). These data indicate that the adoptive 
transfer of WT CD34+ cells results in IH that is broadly similar 
in phenotype to the basal disease developing after endoluminal 
injury in WT mice.
Confirmation That TF on Myofibrocytes Is Involved in 
IH and Associates With Angiopoietin-2 Expression
Wild-type CD34+ cells were incubated with an inhibitory anti-
TF antibody prior to transfer into injured WT mice. IH was com-
pletely inhibited in these mice, compared to mice injected with 
cells incubated with isotype control antibody (Figures  2A–C). 
Pre-treatment with anti-TF antibody induced a significant reduc-
tion in the proportion of angiopoietin-2+ cells in the neointima, 
but also caused a significant reduction in the proportion of col-
lagen-1+ cells recruited (Figure 2D).
Adoptively transferred CD34+ cells contain numerous subpo-
pulations, and these data imply that inhibition of TF on all 
subpopulations has a significant impact on the recruitment of 
fibrocytes, akin to findings we have previously described in a sec-
ond strain of transgenic mice (8), but not directly relevant to the 
question being addressed by this experimental work.
To assess the impact of TF inhibition on myofibrocytes only, 
we adoptively transferred CD34+ cells from CD31-TFPI-Tg 
mice. These mice mobilize similar subpopulations of CD34+ 
cells into the circulation as WT mice, but constitutively express 
cell-surface hTFPI fusion protein only on myofibrocytes (8). We 
have previously shown that transfer of CD34+ cells from these 
mice inhibits the development of IH (8). After adoptive trans-
fer, a significant proportion of the cells recruited to the site of 
injury are collagen-1+ but angiopoietin-2 negative (Figure 3A). 
The small amount of neointima present at day 28 contained a 
majority of collagen-1+, hTFPI+, and angiopoietin-2-negative 
cells (Figure 3B), confirming that failure to develop IH associ-
ated with absence of angiopoietin-2 expression in the recruited 
myofibrocytes.
We used the constitutive expression of hTFPI to purify myofi-
brocytes, by magnetic bead separation from CD34+ cells; the 
isolated myofibrocytes all expressed CD31, SMA, and collagen-1 
(Figure  4A), confirming our previous description of myofib-
rocytes in these mice, but they were angiopoietin-2 negative 
(see below). To confirm that they expressed cell-surface hTFPI, 
we showed that the cells failed to promote thrombin generation 
FigUre 1 | Comparison of phenotype of intimal hyperplasia in wild-type (WT) animals vs. WT after adoptive transfer of WT CD34+ cells immediately post-injury. 
Panels show immunohistology of representative sections through injured mouse carotid arteries harvested on days post-injury as indicated. All sections stained with 
DAPI (4,6 diamidino-2-phenylindole) nuclear stain (blue) and (red) anti-collagen-1 (a,B), or angiopoietin-2 (c), and (green) anti-angiopoietin-2 (a,B). Yellow indicates 
co-localization. In (c), the adoptively transferred cells came from enhanced yellow fluorescent protein (EYFP) mice, which spontaneously fluoresce as shown. The 
annotated white line defines the junction between neointima and media. (a) Injured mice received no adoptively transferred cells. *On day 0, sections harvested 
within an hour of injury. (B) Mice injected with cells from WT mice. (c) Mice injected with cells from EYFP mice. Expanded area illustrates that most of the early 
recruited cells are adoptively transferred, angiopoietin-2+ cells. Tables beside each panel describe summary of staining from all mice (n = 6), showing the proportion 
of the neointimal area that is positive for collagen-1, angiopoietin-2 or both or EYFP, angiopoietin-2 or both on days 0, 5/7, and day 28 (% ± SEM). Data derived 
from three random sections from each of the arteries from each mouse (see Materials and Methods). Subtracting the proportional area occupied by dual positive 
cells from the total area occupied by angiopoietin-2+ cells suggests the proportional area occupied by collagen-1-negative cells expressing angiopoietin-2. *cf WT 
(no adoptive transfer) at equivalent time: p < 0.001. †cf WT (no adoptive transfer) at equivalent time, p = NS. #cf WT (no adoptive transfer) at equivalent time 
p = 0.04. Experiments repeated at least twice.
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FigUre 2 | Pre-incubation of wild-type (WT) CD34+ cells with an inhibitory anti-TF antibody prior to adoptive transfer. (a) Neointimal area (left axis, black bars) 
and intima:media ratio (right axis, white bars) of vessels taken from WT animals 28 days post-injury compared to those in mice after adoptive transfer  
of 1 × 106 WT CD34+ cells that were either pre-incubated with isotype control or an anti-TF antibody immediately prior to injury. Data derived from examination 
of three random sections from five different vessels. *p < 0.01. (B,c) Cross sectional images of WT carotid artery 28 days post-injury stained with elastin van 
Gieson’s stain after adoptive transfer of cells pre-incubated with isotype control antibody (B) or anti-TF antibody (c) prior to injury. (D) Panels show 
immunohistology of consecutive sections through injured mouse carotid arteries harvested on day 5 post-injury. All sections stained with DAPI (4,6 diamidino-
2-phenylindole) nuclear stain (blue) and anti-collagen-1 (red) and (green) angiopoietin-2. Yellow indicates co-localization. The annotated white line defines the 
junction between neointima and media. Table besides panel (D) describes summary of staining from all mice (n = 6), showing the proportion of the neointimal 
area that is positive for collagen-1, angiopoietin-2, or both on day 28 (% ± SEM). Data derived from three random sections from each of the arteries from  
each mouse (see Materials and Methods). Subtracting the proportional area occupied by dual positive cells from the total area occupied by angiopoietin-2+ 
cells gives the proportion of neointimal collagen-1-negative cells expressing angopoietin-2. *cf WT with isotype control p < 0.001 Experiments repeated at 
least twice.
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in the presence of FXa and prothrombin (in contrast to control 
CD34+ cells from WT mice), consistent with the known inhibi-
tory effect of cell-surface hTFPI, which inhibits FXa (Figure 4B).
Injection of these purified hTFPI+ CD31+ myofibrocytes into 
injured WT mice inhibited the development of IH (Figures 4C,E), 
in contrast to injection of the hTFPI-CD31-negative fraction 
of CD34+ cells, following which IH developed as in WT mice 
(Figures 4D,E). The injected hTFPI+ CD31+ myofibrocytes were 
recruited to the site of injury, as evidenced by staining for hTFPI, 
but they remained angiopoietin-2-negative (Figures 4F,G). These 
data confirm that inhibition of TF on the adoptively transferred 
myofibrocytes prevents IH, and that this associates with recruit-
ment of collagen-1+ angiopoietin-2 negative cells to the site of 
injury.
importance of angiopoietin-2 for 
Development of ih
Association Between IH and Plasma Angiopoietin-2 
Levels
Compared to uninjured mice, the concentration of plasma angio-
poietin-2 increased significantly within a few hours post-injury 
(Figure 5A—day “0”), remained significantly elevated in mice 
that developed progressive IH, but fell progressively in mice 
injected with cells from CD31-TFPI-Tg, unless the mice were 
given an anti-TFPI antibody (Figure 5B), in which case plasma 
levels normalized, in association with development of IH. 
Injection of CD34+ cells pre-incubated with anti-TF antibody, 
which inhibited IH, was also associated with a significant 
reduction in plasma angiopoietin-2 levels, (Figure 5C). Plasma 
FigUre 3 | Adoptive transfer of CD31-TFPI-Tg CD34+ cells to wild-type (WT) mice immediately post-injury. Panels show immunohistology of representative 
sections through injured mouse carotid arteries harvested on days post-injury as indicated. All sections stained with DAPI (4,6 diamidino-2-phenylindole) nuclear 
stain (blue) and (red) anti-collagen-1 (a) or human tissue factor pathway inhibitor (B) and (green) anti-angiopoietin-2. Yellow indicates co-localization. The annotated 
white line defines the junction between neointima and media. *On day 0, sections harvested within an hour of injury. Table besides panel (a) describes summary of 
staining from all mice (n = 6), showing the proportion of the neointimal area that is positive for collagen-1, angiopoietin-2, or both on days 0, 7, and 28 (% ± SEM). 
Data derived from three random sections from each of the arteries from each mouse (see Materials and Methods). *cf WT cells (see Figure 1B) at equivalent time 
point p = 0.03. †cf WT cells (Figure 1B) at equivalent time point p < 0.001. Experiments repeated at least twice.
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angiopoietin-1 levels were not influenced under these condi-
tions (Figures 5A,B). These data indicate an association between 
development of IH and plasma angiopoietin-2 levels.
Angiopoietin-2 Expression by Myofibrocytes Is TF 
and Thrombin-Dependent
The majority of CD34+ cells harvested 2  days post-injury 
express functional TF (5): this was confirmed on WT CD34+ 
cells by showing that thrombin was generated when cells were 
incubated with FX and prothrombin when FVIIa was present 
(Figure 6A). The WT CD34 cells secreted angiopoietin-2 under 
these conditions, and also proliferated (Figures 6A,B), whereas 
purified hTFPI-expressing myofibrocytes made no thrombin, 
angiopoietin-2, and failed to proliferate under identical con-
ditions. Angiopoietin-2 secretion by WT  cells under these 
conditions was predominantly PAR-1-dependent (Figure  6C). 
However, reduced quantities were detected when WT cells (but 
not hTFPI+ myofibrocytes) were incubated with FVIIa and FX 
without prothrombin (Figure 6A), suggesting that some of the 
secreted angiopoietin-2 was TF- but not thrombin-dependent; 
under these conditions, PAR-2 signaling was as important as 
PAR-1 (Figure 6C). Consistent with these data, a PAR-1 agonist 
induced greater secretion of angiopoietin-2 compared to an 
equimolar concentration of PAR-2 agonist (Figure 6D). Finally, 
PAR-1-dependent angiopoietin-2 secretion partially involved 
signaling through p42/p44 ERK, p38 kinase, and NFkB pathways, 
but not S6K1 (Figure 6E). PAR-2-induced angiopoietin-2 secre-
tion was also partially inhibited by blocking these same pathways 
but none of the results reached statistical significance. All these 
data indicate that on WT cells, TF promotes secretion of angio-
poietin-2 and induces proliferation, mainly via generation of 
thrombin through canonical PAR-1 signaling pathways, and that 
these effects are completely inhibited by the presence of hTFPI on 
the surface of CD31+ myofibrocytes from CD31-TFPI-Tg mice.
Thrombin-Dependent Proliferation of 
Myofibrocytes is angiopoietin-2-
Dependent
We have previously shown that a 5-day incubation with throm-
bin expands the proportion of myofibrocytes present in CD34+  
cells from 3 to 80%, via a combination of selective outgrowth and 
reduced apoptosis (5). We repeated these in vitro experiments, 
and showed that the proportion of CD34+ cells expressing angio-
poietin-2 increased from 20 to 100%, angiopoietin-2 secretion 
was induced in a dose-dependent manner, and this was partly 
inhibited by siRNA against angiopoietin-2 (Figures  7A,B). 
Similar results were seen when purified CD31+ myofibrocytes 
from CD31-TFPI-Tg mice were incubated with thrombin, though 
these cells were angiopoietin-2 negative at baseline. Therefore, 
these data indicate that the thrombin-induced outgrowth of 
myofibrocytes associates with angiopoietin-2 expression and 
secretion by CD31+ myofibrocytes.
FigUre 4 | Isolation and characterization of CD31+ myofibrocytes from CD31-TFPI-Tg mice. (a) Immunocytofluorescence analysis of CD34+ cells from wild-type 
(WT) (black bars) or CD31-TFPI-Tg (white bars) mice compared to the purified fraction of CD34+ cells that express human tissue factor pathway inhibitor (hTFPI)  
on the cell surface (gray bars). Cells were stained with antibodies against anti-smooth muscle actin and either collagen-1 or CD31, and the proportion of cells 
expressing each was determined. Data are derived from counting at least 100 stained cells from each of five different animals. (B) Thrombin generation assay: 
CD34+ cells from WT (white bars) or purified CD31+ myofibrocytes from CD31-TFPI-Tg (black bars) were incubated with FXa, FVa, and prothrombin as described  
in Section “Materials and Methods,” and supernatants harvested at the times indicated for analysis of the amount of thrombin generated. (c–g) Comparison of the 
functional impact, after adoptive transfer, of the cell-surface hTFPI+ and hTFPI-negative fractions of CD34+ cells from CD31-TFPI-Tg mice. (c,D) Cross sectional 
images of WT carotid artery 28 days post-injury stained with elastin van Gieson’s stain after adoptive transfer of cell-surface hTFPI+ fraction (c) or hTFPI-negative 
fraction (D) on day of injury. (e) Neointimal area (left panel) and intima:media ratio (right panel) of vessels taken from WT animals 28 days post-injury after adoptive 
transfer of 1 × 106 hTFPI-negative (black bars) or hTFPI-positive (white bars) fractions. Data derived from examination of three random sections from five different 
vessels. *p < 0.01. (F,g) Immunohistology of sections through WT injured mouse carotid arteries harvested 28 days post-injury. All sections stained with DAPI  
(4,6 diamidino-2-phenylindole) nuclear stain (blue) and (red) anti-collagen-1 and (green) anti-hTFPI. Yellow indicates co-localization. The annotated white line defines 
the junction between neointima and media. Mice received cell-surface hTFPI-negative fraction (F) or cell-surface hTFPI+ fraction (g) of CD34+ cells on day of injury. 
Table besides panels (F,g) describes summary of staining from all mice (n = 6), showing the proportion of the neointimal area that is positive for collagen-1, hTFPI, 
or both on day 28 (% ± SEM). Data derived from three random sections from each of the arteries from each mouse (see Materials and Methods). Subtracting the 
proportional area occupied by dual positive cells from the total area occupied by hTFPI+ cells gives the proportional area occupied by non-adoptively transferred 
collagen-1-positive cells. *cf hTFPI-negative fraction p = NS. All experiments repeated at least twice.
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These thrombin-induced changes in the composition of the 
CD34+ population were inhibited by an anti-TIE-2 antibody and 
by the siRNA against angiopoietin-2 (Figure 7C), suggesting that 
they were mediated by the angiopoietin-2 secretion induced by 
thrombin. In support of this, a 5-day incubation with angiopoi-
etin-2 induced the same changes as thrombin, and this was inhi-
bited by an anti-TIE-2 antibody (Figure 7D). Using a combination 
of siRNA, anti-TIE-2, and incubation with angiopoietin-2 alone, 
FigUre 5 | Association between intimal hyperplasia and plasma levels of angiopoietin-2 after wire-induced endoluminal injury. (a) Plasma angiopoietin-2 
levels in wild-type (WT) mice. Levels in unninjured mice represented by the horizontal bar day 0 only; (squares)—WT CD34+ cells; (circles)—unfractionated 
CD31-TFPI-Tg CD34+ cells; (diamonds) human tissue factor pathway inhibitor (hTFPI)+ fraction of CD31-TFPI-Tg CD34+ cells; (triangles)—hTFPI-negative 
fraction of CD31-TFPI-Tg CD34+ cells. *Day 7 p < 0.01: WT vs. CD31-TFPI-Tg cells; WT cells vs. hTFPI+ fraction; CD31-TFPI-Tg cells vs. hTFPI−  
fraction and hTFPI− fraction vs. hTFPI+ fraction. All other comparisons, p > 0.05. **Day 28, p < 0.01: WT vs. CD31-TFPI-Tg cells; WT cells vs. hTFPI+ 
fraction; p < 0.01: CD31-TFPI-Tg cells vs. hTFPI− fraction and hTFPI− fraction vs. hTFPI+ fraction. All other comparisons, p > 0.05. (B): Plasma 
angiopoietin-1 (black bars, left axis) and angiopoietin-2 (white bars, right axis) levels, in ng/ml, measured on day 3 post-injury. The strain of mice and whether 
they underwent injury is indicated. CD31-TFPI-Tg mice received anti-hTFPI antibody on day of injury as indicated. †p = 0.08. (c): plasma angiopoietin-1  
(black bars, left axis), and angiopoietin-2 (white bars, right axis) levels in ng/ml, measured on day 3 post-injury, after adoptive transfer of 1 × 106 WT CD34+ 
cells that were either pre-incubated with isotype control or an anti-TF antibody immediately prior to injury. A non-injured control is also included for  
comparison. †p < 0.05.
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we showed that angiopoietin-2, via TIE-2 was responsible for 
both the enhanced proliferation (Figures 7E,F), and the reduced 
apoptosis of myofibrocytes induced by thrombin (Figure  7G). 
As anticipated, the different conditions had little impact on the 
expression of CD31 or SMA by purified CD31+ myofibrocytes 
(Figures 7C,D), but these data indicate that the effect of angio-
poietin-2 on proliferation and apoptosis was a direct effect on the 
myofibrocytes.
FigUre 6 | Impact of coagulation proteases on myofibrocyte phenotype. In (a,B), responses of wild-type (WT) CD34+ cells are shown as white bars, whereas 
isolated CD31+ myofibrocytes from CD31-TFPI-Tg mice are shown as black bars. (a) Cells were incubated with FX in presence or absence of FVIIa and FII 
(prothrombin) plus FVa. Functional tissue factor on WT cells is illustrated by thrombin generation, angiopoietin-2 (Ang-2) secretion, and CXCL-12 secretion. The 
presence of human tissue factor pathway inhibitor on purified CD31+ myofibrocytes from CD31-TFPI-Tg mice significantly inhibits all three phenotype changes.  
(B) Proliferation, assessed by 3H-thymidine incorporation and expressed as counts per minute (CPM) after incubation with FX and FII in presence of FVIIa.  
(c) Angiopoietin-2 secretion by WT CD34+ cells (3 × 104/well) after 24 h incubation with either PAR-1 antagonist (black bars), PAR-2 antagonist (white bars), or 
PAR-4 antagonist (gray bars) at the indicated concentrations for 30 min before addition of FVIIa with FX (both 10 nM) with or without prothrombin (4 nM) and FVa 
(6 nM) as indicated. All conditions performed in triplicate wells. Error bars indicate SEM. In comparison of increasing concentrations of antagonists with FVIIa + FX, 
p = 0.027 for PAR2, but p = NS for PAR1 and PAR4. In comparison of increasing concentrations of antagonists with FVIIa + FX + FII + FVa, p = 0.05 for PAR1, but 
p = not significant (NS) for PAR2 and PAR4. Analysis by one-way ANOVA Kruskal–Wallis test. (D) Angiopoietin-2 secretion by WT CD34+ cells (3 × 104/well) after 
24 h incubation with PAR-1, -2, or -4 agonists at the indicated concentrations. All conditions performed in triplicate wells. Error bars indicate SEM. p = 0.017 for 
comparisons of increasing concentrations of PAR1 agonist, p = 0.012 for PAR2, but p = NS for PAR4 agonist. Analysis by one-way ANOVA Kruskal–Wallis test.  
(e) Dissection of signaling pathways involved in angiopoietin-2 secretion by WT CD34+ cells induced by 24 h incubation with 10 mM PAR-1 or -2 agonists. Cells 
were incubated with the agonists with or without 50 mM mitogen-activated protein kinase inhibitor PD98059, 10 mM p38-MAPK inhibitor SB203580, 20 mM NF-kB 
inhibitor SN50, or 1 mM of the S6K1 inhibitor as indicated. All conditions performed in triplicate wells. Error bars indicate SEM. p = 0.05 for PAR-1 agonist without 
inhibitor vs. +PD98509 and vs. +SB203580. p = > 0.05 all other comparisons. Analysis by Mann–Whitney T test. All experiments repeated at least twice.
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FigUre 7 | Continued
11
Chen et al. Myofibrocyte Angiopoietin-2 and IH
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1517
FigUre 7 | Thrombin-induced proliferation and survival are angiopoietin-2-dependent. In all, responses of wild-type (WT) CD34+ cells are shown as white bars, 
whereas purified CD31+ myofibrocytes from CD31-TFPI-Tg mice are shown as black bars. 0*Indicates incubation with active site inhibited thrombin. Abbreviations: 
Csi, control scrambled siRNA; Ang-2si, siRNA specific for angiopoietin-2. (a) Expression of angiopoietin-2 at baseline and after incubation with thrombin for 5 days, 
expressed as the percentage of CD34+cells staining positive in immunocytofluoresence analysis. (B) Secretion of angiopoietin-2 into supernatant after 5-day 
incubation with thrombin at the indicated concentrations, analyzed by ELISA. (c) Expression of smooth muscle actin (SMA) and joint expression of CD31 with SMA 
at baseline and after incubation with thombin for 5 days, either alone or with anti-TIE-2 antibody or siRNA against angiopoietin-2 or control. Data expressed as the 
percentage of CD34+ cells staining positive in immunocytofluoresence analysis. (D) As (c) but cells incubated with angiopoietin-2 ± anti-TIE-2 antibody.  
(e) Proliferation, assessed by 3H-thymidine incorporation and expressed as counts per minute (CPM) after incubation with thrombin at the indicated concentrations. 
(F) Proliferation, assessed by 3H-thymidine incorporation and expressed as CPM after incubation with angiopoietin-2 at the indicated concentrations.  
(g) Degree of apoptosis after incubation with thrombin or angiopoietin-2 at the indicated concentrations. Anti-TIE-2 antibody used at 50 ng/ml.  
All experiments repeated at least twice.
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ih In Vivo is angiopoietin-2-Dependent
After adoptive transfer, CD34+ cells from EYFP mice incu-
bated with an anti-TIE-2 monoclonal antibody or siRNA against 
angiopoeitin-2 were recruited to the area of damage, but develop-
ment of IH was inhibited, compared to controls (Figures 8A,B). 
Recruited EYFP cells were still angiopoietin-2+ after incubation 
with the anti-TIE-2 (Figure  8C), and there was evidence of 
angiopoietin-2 expression by cells other than myofibrocytes at 
day 28. In contrast, the specific siRNA led to long-term (4-week) 
inhibition of angiopoietin-2 expression by EYFP+ cells and there 
was no evidence of angiopoietin-2 expression by other neointimal 
cells (Figure 8C). This data suggest that angiopoietin-2 secretion 
by recruited myofibrocytes was responsible for angiopoietin-2 
expression by other cells in the vessel wall, but that both angio-
poietin-2 AND intact TIE-2 signaling on myofibrocytes was 
needed to develop IH.
continued cXcl-12-Dependent 
Myofibrocyte recruitment  
contributes to ih
Association Between CXCL-12  
and Angiopoietin-2 In Vivo
In WT mice, a significant proportion of myofibrocytes co- 
expressed CXCL-12 throughout the development of IH (Figure 9A), 
though as with angiopoietin-2 expression, a significant propor-
tion of collagen-1-negative intimal cells also expressed CXCL-12. 
A similar pattern of staining was seen after adoptive transfer of 
WT cells (Figure 9B). At the earliest time point, it was appar-
ent that some of the luminal CXCL-12 staining appeared to 
be independent of collagen-1 (Figure  9B). Most neointimal 
cells also expressed CXCR4 throughout the period post-injury 
(Figure 9C).
In mice that received CD34+ cells treated with an anti-TF 
antibody, CXCL-12 expression in the neointima was abolished, 
but with the caveat mentioned above that few myofibrocytes were 
recruited (Figure 10A). After adoptive transfer of CD34+ cells 
from CD31-TFPI-Tg mice, most of the hTFPI+ cells recruited 
to the site of injury were CXCL12 negative (Figure  10B), and 
all became CXCL-12-negative with increasing time from the 
injury. As with WT  cells, early (but not late) luminal CXCL-
12-expression appeared to be independent of the adoptively 
transferred cells (Figure 10B). CXCR4 was also seen co-localized 
with hTFPI at early time points (Figure 10C), suggesting that the 
initial myofibrocytes recruited immediately after injury expres-
sed CXCR4, but expression faded with time, so that neointimal 
cells 28 days post-injury were mostly CXCR4-negative.
As for plasma angiopoietin-2 levels, post-injury plasma 
CXCL-12 levels increased over the first week and remained high 
in mice that received WT CD34+ cells, but reduced in mice 
receiving CD34+ cells from CD31-TFPI-Tg mice (Figure 11A). 
These differences were specific, as levels of another TF and 
thrombin-dependent chemokine macrophage migration inhibi-
tory factor (12) were similar in both groups of mice (Figure 11A). 
These data suggested that, as for angiopietin-2, levels of CXCL-12 
in the blood correlated closely with the development of IH.
late Myofibrocyte recruitment  
is cXcl-12-Dependent
To demonstrate that myofibrocyte CXCL-12 was relevant for 
continued myofibrocyte recruitment, some mice received an 
injection of CD34+ cells from EYFP mice, 1 week after injection 
of WT  cells. The EYFP CD34+ cells were pre-incubated with 
either an anti-CXCR4 antibody or an isotype control. Whereas 
EYFP cells exposed to the isotype control were found in the 
intima 1 week later, no EYFP+ cells exposed to the anti-CXCR4 
were recruited (Figure  12A), strongly suggesting that the late 
recruitment of cells to the neointima was CXCR4-dependent. 
When these mice had first received cells from CD31-TFPI-Tg 
mice, there was no evidence of recruitment of EYFP cells when 
vessels were examined 1 week later (Figure 12B), even in control 
cells, indicating that the absence of CXCL-12 secretion by neoin-
timal hTFPI+ myofibrocytes prevented continued myofibrocyte 
recruitment.
cXcl-12 secretion by Myofibrocytes is TF 
and angiopoietin-2-Dependent
To explore the link between TF, thrombin, angiopoietin-2, and 
CXCL-12, we incubated WT CD34 cells with FX, FVIIa, and 
prothrombin; these cells secreted CXCL-12, whereas purified 
hTFPI-expressing myofibrocytes made little under identical con-
ditions (Figure 6A). CXCL-12 from WT CD34+ cells under these 
conditions was predominantly PAR-1-dependent (Figure 11B). 
Reduced quantities were secreted when WT cells were incubated 
with FVIIa and FX without prothrombin (Figure 6A), and under 
these conditions, PAR-2 signaling was as important as PAR-1 
(Figure 11B). However, as for angiopoietin-2, a PAR-1 agonist 
induced greater secretion of CXCL-12 compared to an equimolar 
FigUre 8 | Pre-incubation of enhanced yellow fluorescent protein (EYFP) CD34+ cells with reagents to target angiopoietin-2 prior to adoptive transfer.  
(a) Neointimal area (left axis, white bars) and neointima:media ratio (right axis, black bars) of vessels taken from wild-type (WT) animals 28 days post-injury after 
adoptive transfer of 1 × 106 EYFP CD34+ cells that were either pre-incubated with isotype control antibody, an anti-TIE-2 antibody, control scrambled siRNA or 
specific siRNA targeting angiopoietin-2, and administered immediately post-injury. Data derived from examination of three random sections from six different vessels. 
*p < 0.001, †p < 0.001. (B) Cross sectional images of WT carotid artery 28 days post-injury stained with elastin van Gieson’s stain after adoptive transfer of cells 
pre-incubated with the same reagents as above. (c) Panels show immunohistology of sections through injured mouse carotid arteries harvested on day 28 
post-injury. All sections stained with DAPI (4,6 diamidino-2-phenylindole) nuclear stain (blue) and anti-angiopoietin-2 (red). The green staining is light emitted by the 
EYFP cells themselves. Yellow indicates co-localization. The annotated white line defines the junction between neointima and media. Compared to the cells 
incubated with isotype control antibody, the anti-TIE-2 antibody significantly reduced the neointimal area but did not inhibit angiopoietin-2 expression. Compared to 
the scrambled siRNA, the specific siRNA targeting angiopoietin-2 significantly reduced the neointimal area in association with abolition of angiopooietin-2 expression 
by EYFP cells. Tables besides panel (c) describe summary of staining from all mice (n = 6), showing the proportion of the neointimal area that is positive for EYFP, 
angiopoietin-2, or both on day 28 (% ± SEM). Data derived from three random sections from each of the arteries from each mouse (see Materials and Methods). 
Subtracting the proportional area occupied by dual positive cells from the total area occupied by angiopoietin-2+ cells gives the proportional area occupied by 
non-adoptively transferred angiopoietin-2+ cells. *cf isotype for anti-TIE-2 p < 0.001. †cf isotype for anti-TIE-2 p = NS. #cf scrambled siRNA p < 0.001. Experiments 
repeated at least twice.
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FigUre 9 | Association between CXCL-12 and intimal hyperplasia (IH). Panels show immunohistology of representative sections through injured mouse carotid 
arteries harvested on days post-injury as indicated. Sections from same day are consecutive. All sections stained with DAPI (4,6 diamidino-2-phenylindole) nuclear 
stain (blue) and (red) anti-collagen-1, and (green) anti-CXCL-12 (a,B) or CXCR4 (c). Yellow indicates co-localization. The annotated white line defines the junction 
between neointima and media. (a) Injured mice that received no adoptively transferred cells. (B,c) Adoptive transfer of wild-type (WT) CD34+ cells to WT mice 
immediately after post-injury. *Sections harvested within an hour of injury. Expanded areas illustrate that most of the early recruited myofibrocytes are expressing 
CXCL-12, though there is luminal CXCL-12 that is independent of collagen-1 at early time periods. Tables beside panels describe summary of staining from all mice 
(n = 6), showing the proportion of the neointimal area that is positive for collagen-1, CXCL-12 (a,B), or CXCR4 (c) or dual positive on days 0, 7, and 28 (% ± SEM). 
Data derived from three random sections from each of the arteries from each mouse (see Materials and Methods). *cf no adoptive transfer (a) at equivalent time 
p < 0.001. †cf no adoptive transfer (a) at equivalent time p = 0.02. Experiments repeated at least twice.
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concentration of PAR-2 agonist, confirming the predominance 
of PAR-1 (Figure  11C). After incubation with thrombin, the 
proportion of WT CD34+ cells expressing CXCL-12 increased 
from 40 to 100% (Figure 13A) and induced CXCL-12 secretion 
(Figure 13B). These thrombin-dependent effects were inhibited 
by an inhibitory anti-TIE-2 antibody and by the siRNA against 
angiopoietin-2, and incubation with angiopoietin-2 induced the 
same changes, also in a TIE-2-dependent manner (Figure 13C).
These data indicate that, alongside proliferation and survival, 
the CXCL-12 secretion induced in myofibrocytes by TF-induced 
FigUre 10 | Recruitment after adoptive transfer with inhibition of tissue factor (TF). Panels show immunohistology of representative sections through injured mouse 
carotid arteries harvested on days post-injury as indicated. Sections from same day are consecutive. All sections stained with DAPI (4,6 diamidino-2-phenylindole) 
nuclear stain (blue) and (red) anti-collagen-1 (a) or human tissue factor pathway inhibitor (hTFPI) (B,c), and (green) anti-CXCL-12 (a,B) or CXCR4 (c). Yellow 
indicates co-localization. The annotated white line defines the junction between neointima and media. (a) Day 28 sections, in wild-type (WT) mice adoptively 
transferred CD34+ cells pre-incubated with istotype control or anti-TF antibody. (B,c) Adoptive transfer of purified CD31+ myofibrocytes from CD31-TFI-Tg mice to 
WT mice immediately post-injury. *Sections harvested within an hour of injury. Expanded areas illustrate that some of the early luminal CXCL-12 staining is 
independent of recruited hTFPI+ cells. Table besides (a) describes summary of staining from all mice (n = 6), showing the proportion of the neointimal area that is 
positive for collagen-1, CXCL-12, or both on day 28 (% ± SEM), whereas those besides (B,c) described proportion that is positive for hTFPI, CXCL-12 (B), CXCR4 
(c), or dual positive on days 0, 7, and 28. Data derived from three random sections from each of the arteries from each mouse (see Materials and Methods). *cf 
isotype for anti-TF p < 0.001. †cf adoptive transfer of WT cells (Figures 9B,c) at equivalent times p < 0.001. Experiments repeated at least twice.
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FigUre 11 | Association between plasma CXCL-12 and intimal hyperplasia (IH): CXCL-12 expression is thrombin and angiopoietin-2-dependent. (a) Plasma 
CXCL-12 (black filled) and migration inhibitory factor (MIF) (white filled) levels post-injury in wild-type (WT) recipients of WT (squares) or CD31-TFPI-Tg (circles) 
CD34+ cells. *Day 7 and day 28 p < 0.005 WT vs. CD31-TFPI-Tg for CXCL-12. p = NS for all comparisons of MIF. (B) CXCL-12 secretion by WTCD34+ cells 
(3 × 104/well) after 24 h incubation with either PAR-1 antagonist (black bars), PAR-2 antagonist (white bars), or PAR-4 antagonist (gray bars) at the indicated 
concentrations for 30 min before addition of FVIIa with FX (both 10 nM) with or without prothrombin (4 nM) and FVa (6 nM) as indicated. All conditions performed  
in triplicate wells. Error bars indicate SEM. (c) Angiopoietin-2 secretion by WT CD34+ cells (3 × 104/well) after 24-h incubation with PAR-1, -2, or -4 agonists  
at the indicated concentrations. All conditions performed in triplicate wells. Error bars indicate SEM. Data shown in (B,c) is from WT CD34+ cells. Abbreviations: 
Csi, control siRNA; Ang-2si, siRNA specific for angiopoietin-2. Experiments repeated at least twice.
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FigUre 12 | Pre-incubation of enhanced yellow fluorescent protein (EYFP) CD34+ cells with reagents to target CXCR4 or angiopoietin-2 prior to adoptive transfer. 
Panels show immunohistology of consecutive sections through injured mouse carotid arteries harvested on day 28 post-injury. All sections stained with DAPI  
(4,6 diamidino-2-phenylindole) nuclear stain (blue) and anti-CXCL-12 (red). The green staining is light emitted by the EYFP cells themselves. Yellow indicates 
co-localization. The annotated white line defines the junction between neointima and media. (a,B) Injured wild-type (WT) mice were adoptively transferred with 
CD34+ cells on day of injury. In (a), the cells came from WT mice. In (B), the cells came from CD31-TFPI-Tg mice. 1 week later, both groups of mice received a 
second adoptive transfer of EYFP CD34+ cells that were pre-incubated with either isotype control antibody or anti-CXCR4 as indicated. Sections were harvested 
1 week later (day 14 post-injury). The annotated white line defines the junction between neointima and media. The anti-CXCR4 prevented late recruitment of 
adoptively transferred CD34+ cells in (a), but in (B), there is no late recruitment of adoptively transferred EYFP cells, even those pre-incubated with control antibody. 
(c) Adoptive transfer of EYFP CD34+ cells to injured WT mice at the time of injury. Cells first incubated with an anti-TIE-2 or isotype control, or siRNA targeting 
angiopoietin-2 or scrambled control. Compared to the control cells and those incubated with isotype control antibody, the anti-TIE-2 antibody significantly reduced 
the neointimal area but did not inhibit angiopoietin-2 expression. Compared to the scrambled siRNA, the specific siRNA targeting angiopoietin-2 significantly 
reduced the neointimal area in association with abolition of angiopoietin-2 expression cells. Tables besides panels describe summary of staining from all mice (n = 6), 
showing the proportion of the neointimal area that is positive for CXCL-12, EYFP, or both on day of examination (% ± SEM). Data derived from three random 
sections from each of the arteries from each mouse (see Materials and Methods). *cf isotype for anti-TIE-2 p < 0.001. †cf scrambled siRNA p < 0.001. Experiments 
repeated at least twice.
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FigUre 13 | CXCL-12 expression is thrombin and angiopoietin-2-dependent. (a) Expression of CXCL-12 at baseline and after incubation with thrombin or 
angiopoietin-2 for 5 days, expressed as the percentage of cells staining positive in immunocytofluorescence analysis. Anti-TIE-2 antibody used at 50 ng/ml.  
(B) Secretion of CXCL-12 into supernatant after 5 day incubation with thrombin at the indicated concentrations, analyzed by ELISA. (c) Secretion of CXCL-12  
into supernatant after 5 day incubation with angiopoietin-2 at the indicated concentrations, analyzed by ELISA. All data shown from WT CD34+ cells.  
Abbreviations: Csi, control siRNA. Ang-2si, siRNA specific for angiopoietin-2. Experiments repeated at least twice.
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activation of coagulation proteases was mostly thrombin and 
PAR-1-dependent, and was mediated via angiopoietin-2 secre-
tion and interaction with TIE-2.
Finally, to confirm the link between angiopoietin-2 and 
CXCL-12 in  vivo, we demonstrated that adoptively transferred 
EYFP+ CD34+ cells recruited to the site of injury expressed 
CXCL-12 (Figure  12C). However, EYFP CD34+ cells treated 
prior to transfer with either an anti-TIE-2 monoclonal antibody 
or siRNA against angiopoietin-2 made little CXCL-12 compared 
to controls (Figure 8 NEW Figure 12C), supporting the in vitro 
findings that CXCL-12 production was angiopoietin-2 and 
TIE-2-dependent.
DiscUssiOn
Intimal hyperplasia following vascular injury occurs because 
of a progressive accumulation of cells expressing SMA in the 
neointima, which together with vascular remodeling, causes 
stenosis and ischemia of downstream tissues. Although the 
origin of neointimal SMA+ cells in some models of IH remains 
contentious, in our early work with both wire-induced injury 
and allogeneic aortic transplant models (4), we showed that a 
BM-derived cell type, subsequently identified as a myofibrocyte, 
had a critical influence on the development of IH (5, 6). On 
discovering that these cells were mobilized into the circulation 
immediately post-injury, we developed two adoptive transfer 
models, whereby CD34+ cells isolated from post-injury donor 
mice are transferred to host mice either on the day of host mouse 
injury or 7 days post-allogeneic transplantation (4, 5, 8). Under 
both these conditions, the transferred donor cells are recruited 
early to the sites of injury.
These adoptive transfer models, which we show here reflect 
closely the disease that develops in WT mice, offer controlled 
experimental systems in which to study the cellular basis of IH. 
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Transferred CD34+ cells from either WT or CD31-TFPI-Tg mice 
contain approximately 25–50% fibrocytes (CD34+, collagen-1+ 
CD45+), 20% of which are myofibrocytes (SMA+) and some of 
these (i.e., approximately 5% of the transferred CD34+ cells) are 
of the phenotype (CD31+) that gets recruited to the vessel wall 
(5, 8). We demonstrate here that these recruited cells, as well as 
undergoing hyperplasia at the site of injury, also induce changes 
in host vessel wall cells. Our findings, therefore, do not challenge 
or contradict the evidence that other cells types, such as those 
derived from smooth muscle cells, play an important role in IH 
(13, 14), but they do suggest that the involvement of other cell 
types may be orchestrated or regulated by myofibrocytes.
Fibrocytes were re-defined in the modern era in a mouse model 
of wound healing as myeloid cells expressing CD34 and col-
lagen-1. SMA expression has been described (“myofibrocytes”), 
in association with IH in ovine (15) and rat models. Fibrocytes 
expressing low levels of CD31 (16) have been described but their 
function has not been defined.
Having previously defined the significance of TF expres-
sion by myofibrocytes, in this new work we confirm that IH 
is TF-dependent using two orthogonal approaches. First, we 
capitalized on the fact that, for a reason not yet clarified, in 
CD31-TFPI-Tg mice, CD31+ myofibrocytes are the only CD34+ 
subpopulation that express the hTFPI fusion protein on their cell 
surface, allowing us to isolate them from other CD34+ subpopu-
lations, and confirm that adoptive transfer of this subset  alone 
was able to completely inhibit IH, whereas the remaining, cell 
surface hTFPI-negative fractions failed to inhibit, thus establish-
ing that the protected phenotype of parental transgenic mice was 
due entirely to cell surface expression of hTFPI (and inhibition of 
TF) on this subset. Second, incubation of WT CD34+ cells with 
an anti-TF antibody prior to adoptive transfer completely inhib-
ited subsequent development of IH, confirming that preventing 
coagulation protease activation on the surface of the injected 
CD34+ cells was sufficient to prevent IH. However, inhibition of 
TF on all subsets of CD34+ cells appeared to have a significant 
effect on the recruitment of collagen-1+ cells. These two distinct 
effects of TF inhibition are completely consistent with our previ-
ous findings (8).
Furthermore, we defined the mechanism through which TF 
induces hyperplasia of myofibrocytes in  vitro. TF with FVIIa 
and FX upregulated production of angiopoietin-2, primarily 
via thrombin generation, which then directly induced TIE-2-
dependent proliferation, reduced spontaneous apoptosis, and 
induced CXCL-12 production. The relevance of these for IH 
in vivo was directly demonstrated by showing that prior treatment 
of adoptively transferred CD34+ cells with either an anti-TIE-2 
or siRNA to angiopoietin-2 completely inhibited the develop-
ment of IH (see Figure 14). Our experimental approach, being 
able to isolate CD31+ myofibrocytes from CD31-TFPI-Tg mice, 
allowed us to show that the effect of thrombin and angiopoietin-2 
was a direct effect on the myofibrocytes, and did not involve 
responses from other CD34+ subpopulations.
Angiopoietin-2 was first defined at sites of vascular remodeling 
(17) where it disrupted angiogenesis, and is now thought to act 
as an autocrine factor, sensitizing (and destabilizing) endothe-
lium to activation by other stimuli. Physiologically, these effects 
are counteracted by angiopoietin-1, made by pericytes in situ, 
which play an important role in maintaining endothelial cell 
homeostasis (18). These antagonistic effects of angiopoietins-1 
and -2 are mediated through their mutual receptor TIE-2 and are 
thought to be important for maintenance of vascular quiescence 
(19). Angiopoietin-2 also has direct effects, via TIE-2 signaling 
on some leukocytes (20), including acting as a chemoattractant 
for monocytes (21) and neutrophils (22) modifying the cytokine 
profiles of TIE-2 expressing monocytes (23, 24) and has been 
recently shown to mediate the thrombin-mediated adhesion 
of monocytes to EC (25). These effects of angiopoietin-2 have 
been linked to IH in several models (26, 27), and protection 
against IH linked to antagonism by angiopoietin-1 (28), but 
our findings provide the first detailed understanding, on the 
molecular and cellular level, of how angiopoiein-2 regulates 
the development of IH by linking coagulation proteases with 
chemokine signaling.
Angiopoietin-2 is constitutively expressed by EC, but expres-
sion by other cell types has been described, including myofibro-
blasts in healing wounds (29) and monocytes during sepsis (30), 
so our description of a subset of fibrocytes making angiopoietin-2 
after stimulation with coagulation proteases is consistent with 
these previous reports. The association between plasma angio-
poietin-2 levels and development of IH is consistent with the 
neointimal fibrocytes being the main source of plasma angio-
poietin-2 in this model.
Early recruitment of myofibrocytes to the site of injury 
in this model of IH is known to involve CXCL-12, released 
from platelets that rapidly adhere to areas of endothelial denu-
dement (31, 32). In light of our previous demonstration that 
platelets adhere rapidly to the site of injury for up to 3  days 
in this model (6), our new data showing luminal CXCL-12 
staining, independently of collagen-1, in sections from a few 
hours post-injury, is consistent with expression by platelets. 
We also previously showed that labeled CD34+ cells injected 
up to 2 weeks after injury were still recruited to the neointima, 
suggesting that continued recruitment of CD31+ myofibrocytes 
from the circulation may contribute to the progressive IH. 
Our new data are consistent with other reports describing the 
importance of CXCL-12/CXCR4 for progressive IH (33, 34). 
We have confirmed that this continued recruitment required 
CXCR4 on the recruited cells and ongoing CXCL-12 expres-
sion by neointimal cells, which was associated with sustained 
levels of circulating CXCL-12 post-injury. In vivo, expression of 
hTFPI on CD31+ myofibrocytes inhibited angiopoietin-2 and 
CXCL-12 expression and prevented continued recruitment. 
In vitro, CXCL-12 induced by TF or thrombin was mediated by 
angiopoietin-2 via TIE-2.
In summary, we have provided an in-depth analysis of the 
importance of TF for progressive IH in a model of endoluminal 
injury in mice, first verifying the importance of TF for hyperplasia 
of CD31+ myofibrocytes and then defining the critical impor-
tance of angiopoietin-2 production, which appears necessary for 
proliferation, enhanced survival, and continued recruitment of 
neointimal cells. These data provide important novel insights into 
the pathophysiology of IH and indicate new translational targets 
for investigation and potential exploitation in human disease.
FigUre 14 | Interpretation of our findings. (a) Post-endoluminal injury, fibrocytes (green) are mobilized into the circulation, a subpopulation of which express smooth 
muscle actin (SMA) (“myofibrocytes”-yellow cells) and CD31 and these are recruited to the site of injury, via CXCR4 from CXCL-12 released from luminal platelets 
(data not shown). These myofibrocytes express tissue factor (TF), which generates FXa and thrombin (FIIa), which can signal through PARs-1 and -2 on the cell 
surface. These result in the secretion of angiopoietin-2, which through cell surface TIE-2, causes proliferation and secretion of CXCL-12, which can attract more 
myofibrocytes from the circulation. The myofibrocytes also orchestrate expression of angiopoietin-2 by other cells within the vessel wall, by a mechanism not 
elucidated. (B) Inhibition of TF on the myofibrocytes, either by cell surface expression of a transgenic human tissue factor pathway inhibitor (hTFPI) fusion protein, or 
by an anti-TF antibody inhibits angiopoietin-2 secretion and results in a small neointima, consisting of non-proliferating myofibrocytes. An siRNA to angiopoietin-2 or 
a blocking anti-TIE-2 antibody has the same effect, illustrating the key importance of the angiopoietin-2/TIE axis for the development of intimal hyperplasia. 
*Treatment of whole CD34+ cells with an anti-TF inhibits intimal hyperplasia (IH) but also prevents significant recruitment of myofibrocytes, in a similar way as 
expressing hTFPI fusion protein on SMA+ fibrocytes (8).
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